Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biomin is an animal health and nutrition company focused on feed additives and premixes for livestock and aquaculture. The business built a specialty position in mycotoxin risk management and gut health performance management, with commercial product lines spanning mycotoxin deactivators, probiotics/synbiotics, acidifiers, phytogenics, enzymes, yeast derivatives, and premixes. Historically headquartered in Austria, Biomin was part of Erber Group and was acquired by DSM on October 2, 2020 as part of DSM's acquisition of Erber Group. Today the Biomin brand and product portfolio sit within dsm-firmenich Animal Nutrition & Health, serving farm animal producers globally. Its offerings are aimed at improving animal health, feed efficiency, pathogen control, and production sustainability rather than human therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biomin.